News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Epigenomics AG: Epigenomics signs joint commercialization agreement for Epi proColon(R) in North America with Polymedco

Epigenomics AG / Key word(s): Agreement 02.10.2013 / 08:00 – Companies to join efforts in commercialization of Epi proColon(R) – Epigenomics to provide manufacturing, medical, regulatory and strategic marketing – Polymedco, the US leader in CRC screening products, to contribute logistics, sales, marketing and customer support Berlin, Germany, and U.S.A., October 2, 2013– Epigenomics AG […]

Read more

Epigenomics AG: Epigenomics AG secures financing of up to EUR 5m

Epigenomics AG / Key word(s): Corporate Action 19.08.2013 / 08:30 Berlin, Germany, and U.S.A., August 19, 2013 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, announced that it has entered into an agreement with YA Global Master SPV Ltd. (‘Yorkville’) through which it secured a convertible bond financing […]

Read more

Epigenomics AG: Epigenomics AG Announces H1 2013 and Q2 2013 Financial Results and Reports on Operational Highlights

Epigenomics AG / Key word(s): Half Year Results 07.08.2013 / 08:30 Berlin, Germany, and U.S.A., August 7, 2013 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced its financial results for the first half and second quarter of 2013 ending June 30. Revenue in Q2 2013 increased […]

Read more

Epigenomics: US study suggests blood-based Septin9 CRC screening could save lives and be health-economically beneficial

Epigenomics AG / Key word(s): Study 22.07.2013 / 10:30 Press release Epigenomics: US study suggests blood-based Septin9 CRC screening could save lives and be health-economically beneficial – CRC screening with blood-based Septin9 tests has potential to improve screening uptake and adherence rates – Septin9 testing could decrease colorectal cancer (CRC) incidence by 41% and CRC […]

Read more

Epigenomics AG: Epigenomics Establishes American Depositary Receipt (ADR) Program

Epigenomics AG / Key word(s): Miscellaneous 09.07.2013 / 15:00 Epigenomics Establishes American Depositary Receipt (ADR) Program Epigenomics ADRs can be traded on US over-the-counter (OTC) market effective as of July 9, 2013 ADR ticker symbol EPGNY 1 ADR represents 5 ordinary company shares Berlin, Germany, and U.S.A., July 9, 2013 – Epigenomics AG (Frankfurt Prime […]

Read more

Epigenomics AG: Results of Comparative Study between Epigenomics Epi proColon(R) and FIT to be Presented at Digestive Disease Week

Epigenomics AG / Key word(s): Product Launch/Study 15.05.2013 / 09:00 Results of Comparative Study between Epigenomics Epi proColon(R) and FIT to be Presented at Digestive Disease Week Berlin, Germany, and U.S.A., May 15, 2013 – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today announced that results of the head-to-head comparative […]

Read more